MultiCell Technologies Inc (MCET)

[TPX]

OXS-4235 / MultiCell Technologies, Inc.
Drug Names(s): OXS4235, OXS 4235, P62-ZZ Inhibitor, P62zz Inhibitor

Description: OXS-4235 is an antibody-drug conjugate (ADC) targeting the inhibition of p62 for the treatment of multiple myeloma and osteolytic lesions.

By selectively inhibiting p62 in multiple myeloma cancer cells, stress is induced in the multiple myeloma cancer cells due to the accumulation within the cells of damaged biomolecules that cannot be destroyed via the normal function of the proteasome. As a result of the stress placed on the cancer cells by inhibition of p62, the cancer cells undergo a biological process known as autophagy which results in their destruction.

Deal Structure: MultiCell and Oxis
In March 2015, MultiCell Immunotherapeutics signed a research and development and product license agreement with Oxis Biotech to create three novel antibody-drug conjugates (ADCs) containing OXIS' lead drug candidates using MCIT's proprietary ADC platform technology. These ADC product candidates are to be used by OXIS for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, OXIS paid MCIT a license fee of $500,000, and will reimburse MCIT up to $1.125 million in development costs for the three ADC product candidates. Oxis will also pay up to $12.75 million in clinical development milestones, and was granted an option to purchase manufacturing rights to the three ADCs upon payment of an additional $10 million. OXIS was also granted a worldwide exclusive license to sell the three ADC product candidates, and will pay a royalty of 3% of net yearly sales. MCIT...See full deal structure in Biomedtracker

Partners: Oxis International, Inc.

http://drugprofiles.informa.com/drug_profiles/26167-oxs-4235